A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

This study is testing LCB84, a new type of targeted therapy called an antibody-drug conjugate (ADC) that delivers chemotherapy directly to cancer cells carrying a protein called TROP2, either alone or combined with an immunotherapy drug, in people with advanced solid tumors. **You may be eligible if...** - You have a histologically confirmed advanced solid tumor that has stopped responding to standard treatments - For the expansion phase: you have a specific tumor type identified as eligible by the study - You are in adequate general health and your organs are functioning well enough for treatment **You may NOT be eligible if...** - You have received too many prior lines of treatment or certain prior TROP2-targeted therapies - You have active brain metastases (cancer spread to the brain) - You have serious lung disease or other significant organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.